ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.

W. W. Hope; E. Castagnola; A. H. Groll; E. Roilides; M. Akova; M. C. Arendrup; S. Arikan-Akdagli; M. Bassetti; J. Bille; O. A. Cornely; M. Cuenca-Estrella; J. P. Donnelly; J. Garbino; R. Herbrecht; H. E. Jensen; B. J. Kullberg; C. Lass-Flörl; O. Lortholary; W. Meersseman; G. Petrikkos; M. D. Richardson; P. E. Verweij; C. Viscoli; A. J. Ullmann

doi:10.1111/1469-0691.12040

ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.

W. W. Hope, E. Castagnola, A. H. Groll, E. Roilides, M. Akova, M. C. Arendrup, S. Arikan-Akdagli, M. Bassetti, J. Bille, O. A. Cornely, M. Cuenca-Estrella, J. P. Donnelly, J. Garbino, R. Herbrecht, H. E. Jensen, B. J. Kullberg, C. Lass-Flörl, O. Lortholary, W. Meersseman, G. PetrikkosM. D. Richardson, P. E. Verweij, C. Viscoli, A. J. Ullmann

Research output: Contribution to journal › Article › peer-review

Abstract

Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin±Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used. © 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Original language	English
Pages (from-to)	38-52
Number of pages	14
Journal	Clinical Microbiology and Infection
Volume	18
Issue number	7
DOIs	https://doi.org/10.1111/1469-0691.12040
Publication status	Published - Dec 2012

Keywords

Antifungal agents
Candida disease
Children
Europe
Neonates

Access to Document

10.1111/1469-0691.12040

Cite this

Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., Cuenca-Estrella, M., Donnelly, J. P., Garbino, J., Herbrecht, R., Jensen, H. E., Kullberg, B. J., Lass-Flörl, C., Lortholary, O., Meersseman, W., ... Ullmann, A. J. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp. Clinical Microbiology and Infection, 18(7), 38-52. https://doi.org/10.1111/1469-0691.12040

@article{ed4903c5a81845e49b934065e88909ec,

title = "ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.",

abstract = "Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin±Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used. {\textcopyright} 2012 The Authors. Clinical Microbiology and Infection {\textcopyright} 2012 European Society of Clinical Microbiology and Infectious Diseases.",

keywords = "Antifungal agents, Candida disease, Children, Europe, Neonates",

author = "Hope, {W. W.} and E. Castagnola and Groll, {A. H.} and E. Roilides and M. Akova and Arendrup, {M. C.} and S. Arikan-Akdagli and M. Bassetti and J. Bille and Cornely, {O. A.} and M. Cuenca-Estrella and Donnelly, {J. P.} and J. Garbino and R. Herbrecht and Jensen, {H. E.} and Kullberg, {B. J.} and C. Lass-Fl{\"o}rl and O. Lortholary and W. Meersseman and G. Petrikkos and Richardson, {M. D.} and Verweij, {P. E.} and C. Viscoli and Ullmann, {A. J.}",

year = "2012",

month = dec,

doi = "10.1111/1469-0691.12040",

language = "English",

volume = "18",

pages = "38--52",

journal = "Clinical Microbiology and Infection",

issn = "1469-0691",

publisher = "Elsevier BV",

number = "7",

}

Hope, WW, Castagnola, E, Groll, AH, Roilides, E, Akova, M, Arendrup, MC, Arikan-Akdagli, S, Bassetti, M, Bille, J, Cornely, OA, Cuenca-Estrella, M, Donnelly, JP, Garbino, J, Herbrecht, R, Jensen, HE, Kullberg, BJ, Lass-Flörl, C, Lortholary, O, Meersseman, W, Petrikkos, G, Richardson, MD, Verweij, PE, Viscoli, C & Ullmann, AJ 2012, 'ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.', Clinical Microbiology and Infection, vol. 18, no. 7, pp. 38-52. https://doi.org/10.1111/1469-0691.12040

TY - JOUR

T1 - ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.

AU - Hope, W. W.

AU - Castagnola, E.

AU - Groll, A. H.

AU - Roilides, E.

AU - Akova, M.

AU - Arendrup, M. C.

AU - Arikan-Akdagli, S.

AU - Bassetti, M.

AU - Bille, J.

AU - Cornely, O. A.

AU - Cuenca-Estrella, M.

AU - Donnelly, J. P.

AU - Garbino, J.

AU - Herbrecht, R.

AU - Jensen, H. E.

AU - Kullberg, B. J.

AU - Lass-Flörl, C.

AU - Lortholary, O.

AU - Meersseman, W.

AU - Petrikkos, G.

AU - Richardson, M. D.

AU - Verweij, P. E.

AU - Viscoli, C.

AU - Ullmann, A. J.

PY - 2012/12

Y1 - 2012/12

N2 - Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin±Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used. © 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

AB - Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for the prevention and treatment of IC in neonates and children. Appropriate agents for the prevention of IC in neonates at high risk include fluconazole (A-I), nystatin (B-II) or lactoferrin±Lactobacillus (B-II). The treatment of IC in neonates is complicated by the high likelihood of disseminated disease, including the possibility of infection within the central nervous system. Amphotericin B deoxycholate (B-II), liposomal amphotericin B (B-II), amphotericin B lipid complex (ABLC) (C-II), fluconazole (B-II), micafungin (B-II) and caspofungin (C-II) can all be potentially used. Recommendations for the prevention of IC in children are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children. For allogeneic HSCT recipients, fluconazole (A-I), voriconazole (A-I), micafungin (A-I), itraconazole (B-II) and posaconazole (B-II) can all be used. Similar recommendations are made for the prevention of IC in children in other risk groups. With several exceptions, recommendations for the treatment of IC in children are extrapolated from adult studies, with concomitant pharmacokinetic studies. Amphotericin B deoxycholate (C-I), liposomal amphotericin B (A-I), ABLC (B-II), micafungin (A-I), caspofungin (A-I), anidulafungin (B-II), fluconazole (B-I) and voriconazole (B-I) can all be used. © 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

KW - Antifungal agents

KW - Candida disease

KW - Children

KW - Europe

KW - Neonates

U2 - 10.1111/1469-0691.12040

DO - 10.1111/1469-0691.12040

M3 - Article

C2 - 23137136

SN - 1469-0691

VL - 18

SP - 38

EP - 52

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 7

ER -

ESCMID guideline for the diagnosis and management of Candida diseases 2012: Prevention and management of invasive infections in neonates and children caused by Candida spp.

Abstract

Keywords

Access to Document

Fingerprint

Cite this